Stocks
Basilea IncBSLN
HealthcareBiotechnology
A commercial-stage biopharmaceutical company developing and selling anti-infective and oncology drugs. Its core product, ceftobiprole, targets multidrug-resistant bacterial infections, while its oncology pipeline includes investigational therapies for advanced solid tumors. Investors track the company for its revenue growth from existing hospital products and catalysts from clinical trial readouts.
Congressional Interest in Basilea Inc (BSLN)
1 member of Congress has disclosed 1 trade in Basilea Inc (BSLN), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading BSLN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-08-11 | Kurt Schrader | sell | $1K-$15K |